MannKind vs. Idenix: Better Biotech Buy

In this video after a big day in the biotech sector, Motley Fool health-care analyst David Williamson takes investors through today's big winner and loser.

Idenix is the winner for the day, up 10% after posting solid results in a proof-of-concept trial for its hepatitis-C drug IDX21437. Idenix has also been in the news lately for its lawsuit against Gilead for patent infringement over Sofosbuvir, more commonly known as Sovaldi. The drug is set to do $5 billion in sales in its first year, making the legal battle worthwhile for Idenix, but David doesn't see this as something that should factor into the investing thesis just yet. He also worries about how far behind Idenix is in the hepatitis-C space, with the competition already having drugs showing excellent results in much later stages of development.

Meanwhile, MannKind was the big loser of the day, falling by about 10% after the FDA announced a delay to its PFUFA, or approval decision date, for the company's inhaled insulin Afrezza. After a massive victory for the company last week, with the FDA advisory committee voting overwhelmingly in favor of approving the drug, the FDA's decision to postpone has made some concerned that it will go against the advisory committee's recommendation. David, however, remains unconcerned and thinks that the sell-off today may have been overblown. He still sees a high chance for FDA approval here and gives some ways that he would like to start seeing MannKind prepare for the drug's launch.

Invest in the next wave of health care innovation
The Economist compares this disruptive invention to the steam engine and the printing press. Business Insider says it's "the next trillion-dollar industry." And the technology  behind is poised to set off one of the most remarkable health care revolutions in decades. The Motley Fool's exclusive research presentation dives into this technology's true potential, and its ability to make life-changing medical solutions never thought possible. To learn how you can invest in this unbelievable new technology, click here now to see our free report.

The article MannKind vs. Idenix: Better Biotech Buy originally appeared on

David Williamson has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story